Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer
Kairos Pharma reported positive interim Phase 2 data for ENV-105 (carotuximab) plus apalutamide in metastatic castration-resistant prostate cancer, with a statistically significant PFS benefit (P=0.0008). Median progression-free survival was 17.7 months with the combination versus 2 months with apalutamide alone — a large differential for a first-in-class CD105 antibody targeting drug resistance.
Key figures
- Drug Name
- ENV-105 (carotuximab)
- Phase Of Trial
- Phase 2
- P value
- P=0.0008
- Trial completion target
- Q4 2027 or earlier
- Median pfs control months
- 2
- Median pfs combination months
- 17.7
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.